KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Current Deferred Revenue (2016 - 2017)

Acadia Pharmaceuticals (ACAD) has 7 years of Current Deferred Revenue data on record, last reported at $4.1 million in Q1 2017.

  • For Q1 2017, Current Deferred Revenue changed N/A year-over-year to $4.1 million; the TTM value through Mar 2017 reached $4.1 million, changed N/A, while the annual FY2016 figure was $2.6 million, N/A changed from the prior year.
  • Current Deferred Revenue reached $4.1 million in Q1 2017 per ACAD's latest filing, up from $2.6 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $4.1 million in Q1 2017 and bottomed at $15000.0 in Q3 2014.
  • Average Current Deferred Revenue over 4 years is $876090.9, with a median of $111000.0 recorded in 2013.
  • The widest YoY moves for Current Deferred Revenue: up 69.92% in 2013, down 87.33% in 2013.
  • A 4-year view of Current Deferred Revenue shows it stood at $55000.0 in 2013, then plummeted by 72.73% to $15000.0 in 2014, then skyrocketed by 17526.67% to $2.6 million in 2016, then skyrocketed by 56.28% to $4.1 million in 2017.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $4.1 million in Q1 2017, $2.6 million in Q4 2016, and $1.9 million in Q3 2016.